Tersera Company Profile
What is the competitive landscape for TERSERA
TERSERA has six approved drugs.
There are fourteen US patents protecting TERSERA drugs.
Summary for Tersera
| US Patents: | 14 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 6 |
Drugs and US Patents for Tersera
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tersera | XERMELO | telotristat etiprate | TABLET;ORAL | 208794-001 | Feb 28, 2017 | RX | Yes | Yes | 8,653,094 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Tersera | ZOLADEX | goserelin acetate | IMPLANT;IMPLANTATION | 019726-001 | Dec 29, 1989 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Tersera | VARUBI | rolapitant hydrochloride | TABLET;ORAL | 206500-001 | Sep 1, 2015 | RX | Yes | Yes | 8,178,550 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Tersera | XERMELO | telotristat etiprate | TABLET;ORAL | 208794-001 | Feb 28, 2017 | RX | Yes | Yes | 7,553,840 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Tersera
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Tersera | ZOLADEX | goserelin acetate | IMPLANT;IMPLANTATION | 019726-001 | Dec 29, 1989 | 7,220,247 | ⤷ Start Trial |
| Tersera | VARUBI | rolapitant hydrochloride | TABLET;ORAL | 206500-001 | Sep 1, 2015 | 8,796,299 | ⤷ Start Trial |
| Tersera | ZOLADEX | goserelin acetate | IMPLANT;IMPLANTATION | 019726-001 | Dec 29, 1989 | 5,366,734 | ⤷ Start Trial |
| Tersera | ZOLADEX | goserelin acetate | IMPLANT;IMPLANTATION | 019726-001 | Dec 29, 1989 | 7,500,964 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Tersera Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| New Zealand | 532975 | ⤷ Start Trial |
| South Korea | 20120060215 | ⤷ Start Trial |
| Spain | 2625083 | ⤷ Start Trial |
| Hong Kong | 1111157 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Tersera Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2091940 | CR 2018 00011 | Denmark | ⤷ Start Trial | PRODUCT NAME: TELOTRISTAT OR A C1-4 ALKYL ESTER THEREOF, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR TELOTRISTAT ETHYL, MORE PARTICULARLY HIPPURATE SALT OF TELOTRISTAT ETHYL; REG. NO/DATE: EU/1/17/1224 20170920 |
| 2091940 | 1890014-2 | Sweden | ⤷ Start Trial | PRODUCT NAME: TELOTRISTAT OR A PHARMACEUTICALLY ACCEPTABLE ESTER, OR A SALT THEREOF, IN PARTICULARLY TELOTRISTAT ETHYL, MORE PARTICULARLY HIPPURATE SALT OF TELOTRISTAT ETHYL; REG. NO/DATE: EU/1/17/1224 20170920 |
| 1463716 | 122017000080 | Germany | ⤷ Start Trial | PRODUCT NAME: ROLAPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, EINSCHLIESSLICH ROLAPITANT HYDROCHLORID-MONOHYDRAT; REGISTRATION NO/DATE: EU/1/17/1180 20170420 |
| 1463716 | 2017/042 | Ireland | ⤷ Start Trial | PRODUCT NAME: ROLAPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING ROLAPITANT HYDROCHLORIDE MONOHYDRATE; REGISTRATION NO/DATE: EU/1/17/1180 20170420 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
